RepliCel Life Sciences Inc. (TSXV:RP)

RepliCel Life Sciences Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	1.37	-0.31	-0.74	-4.07	-1.58	-3
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	-0.02	0.24	0.07	0.47	0	0.03
Provision & Write-off of Bad Debts	0.04	0.04	0.04	0.04	0.04	0.04
Other Operating Activities	-2.18	-1.41	-1.04	1.38	-0.14	-0.29
Change in Accounts Payable	0.6	-0.09	0.32	-0.3	0.86	0.03
Change in Unearned Revenue	-0.01	-0.01	-0	-0	0.01	-
Change in Other Net Operating Assets	0.12	0.12	-0.05	-0.02	0.05	0.42
Operating Cash Flow	-0.09	-1.41	-1.41	-2.51	-0.77	-2.78
Investment in Securities	0.02	-	-	-	0.01	-0.03
Investing Cash Flow	0.02	-	-	-	0.01	-0.03
Short-Term Debt Issued	-	0.05	-	-	0.05	-
Long-Term Debt Issued	-	-	-	-	0.06	-
Total Debt Issued	0.41	0.05	-	-	0.11	-
Net Debt Issued (Repaid)	0.41	0.05	-	-	0.11	-
Issuance of Common Stock	-	1.01	1.6	2.7	0.66	-
Financing Cash Flow	0.07	1.06	1.6	2.7	0.76	0.42
Net Cash Flow	-0	-0.35	0.19	0.19	0.01	-2.39
Free Cash Flow	-0.09	-1.41	-1.41	-2.51	-0.77	-2.78
Free Cash Flow Margin	-24.94%	-399.76%	-398.45%	-710.66%	-216.32%	-786.42%
Free Cash Flow Per Share	-0.00	-0.02	-0.04	-0.08	-0.03	-0.12
Levered Free Cash Flow	-0.01	-0.97	-0.58	-1.69	-0.26	-1.94
Unlevered Free Cash Flow	0.05	-0.88	-0.53	-1.6	-0.22	-1.92
Change in Net Working Capital	-0.43	0.25	-0.27	0.63	-0.62	0.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.